Trial reportInternational immunopharmacology2021
Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
Open access · greenAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph
Trial report in International immunopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 4 pooled it
4.4field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Favipiravir for treating COVID-19.The Cochrane database of systematic reviews · 2024Pooled it
- The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Pooled it
- Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials.BMC infectious diseases · 2022Pooled it
- Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.Frontiers in public health · 2021Pooled it
- Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.BMC infectious diseases · 2024Trial
- Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial.Advances in respiratory medicine · 2023Trial
- Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.PLoS medicine · 2022Trial
- Hepatitis is an underestimated complication among children with pneumonia associated with SARS-CoV-2 and influenza: a single center study.BMC pediatrics · 2026Article
- Potential Predictors of the Outcome of Tocilizumab Treatment in Patients with COVID-19-Associated Hyperinflammation.Infectious diseases & clinical microbiology · 2025Article
- Dysregulated glycerophospholipid metabolism in amygdala may mediate favipiravir-induced anxiety-like behaviors in mice.Frontiers in pharmacology · 2025Article
- Observational
- Antivirals in COVID-19: A Focus on Pediatric Cardiac Patients.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Review
- Favipiravir pharmacokinetics in Thai adults with mild COVID-19: A sub-study of interpatient variability and ethnic differences in exposure.Pharmacology research & perspectives · 2024Article
- Evaluation of the relationship of treatment and vaccination with prognosis in patients with a diagnosis of COVID-19.Inflammopharmacology · 2024Article
- Clinical Course and Factors Associated With Hospital Admission and Mortality among Sars-Cov 2 Patients within Nairobi Metropolitan Area.medRxiv : the preprint server for health sciences · 2024Article
- Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies.European journal of clinical pharmacology · 2023Review
- Severe COVID-19: Drugs and Clinical Trials.Journal of clinical medicine · 2023Review
- Comparison of methylprednisolone pulse vs conventional dexamethasone for adult cases of COVID-19 requiring oxygen; a Japanese retrospective cohort study.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2023Article
- Recent advances in small-molecular therapeutics for COVID-19.Precision clinical medicine · 2022Review
- A Single-Centered Cohort Study on Favipiravir Safety and Efficacy in Pediatric Patients with COVID-19.Iranian journal of pharmaceutical research : IJPR · 2022Article
Corrections and comments
- Commented on by
Authors and funding
44 authors at 11 institutions in 2 countries.
Masoud Solaymani-DodaranMinimally Invasive Surgery Research Center, Hazrat-e-Rasool Hospital, Iran University of Medical Science, Tehran, Iran; Division of Epidemiology and Public Health, University of Nottingham, Nottingham, NG7 2UH, UK; School of Public Health, Iran University of Medical Science, Tehran, Iran.
Mostafa GhaneiChemical Injuries Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address: mghaneister@gmail.com.
Mehdi BagheriHealth Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Ali QazviniTrauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Ensieh VahediChemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Seyed Hassan SaadatBehavioral sciences research center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Seyed Amin SetarehdanMinimally Invasive Surgery Research Center, Hazrat-e-Rasool Hospital, Iran University of Medical Science, Tehran, Iran; School of Public Health, Iran University of Medical Science, Tehran, Iran.
Akram AnsarifarSchool of Public Health, Iran University of Medical Science, Tehran, Iran.
Hossein BiganehStudent Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Arash MohazzabSchool of Public Health, Iran University of Medical Science, Tehran, Iran; Reproductive Biotechnology Research Center, Avicenna Research Institute Tehran, ACECR, Tehran, Iran.
Davood KhaliliPrevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Amir Hosein GhazaleStudent Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Mohammad Reza HeidariStudent Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Ali TaheriStudent Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Maliheh KhoramdadSchool of Public Health, Iran University of Medical Science, Tehran, Iran.
Mohammad Mahdi AsadiStudent Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Masoud NazemiehTuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Tabriz, Iran.
Mojtaba VarshochiInfectious and Tropical Disease Research Center, Tabriz University of Medical Science, Tabriz, Iran.
Samaneh AbbasianLiver and Gastrointestinal Disease Research Center, Tabriz University of Medical Science, Tabriz, Iran.
Ali BakhtiariSchool of Medicine, Dezful University of Medical Science, Dezful, Iran.
Reza MosaedFaculty of Medicine, Aja University of Medical Science, Tehran, Iran.
Seyyed-Javad Hosseini-ShokouhInfectious Disease Research Center, Faculty of Medicine, Aja University of Medical Science, Tehran, Iran.
Masoume ShahrokhiSchool of Management, Tehran University, Tehran, Iran.
Zeynab YassinAntimicrobial Resistance Research Center, Iran University of Medical Science, Tehran, Iran.
Mohammad Ali ZohalMetabolic Diseases Research Center, Qazvin University of Medical Science, Qazvin, Iran.
Maryam QaraatiMetabolic Diseases Research Center, Qazvin University of Medical Science, Qazvin, Iran.
Nafiseh RastgooMetabolic Diseases Research Center, Qazvin University of Medical Science, Qazvin, Iran.
Ramin SamiDepartment of Internal Medicine, School of Medicine, Isfahan University of Medical Science, Isfahan, Iran.
Mohammad Javad EslamiSchool of Medicine, Isfahan University of Medical Science, Isfahan, Iran.
Akram AsghariDepartment of Internal Medicine, School of Medicine, Qom University of Medical sciences, Qom, Iran.
Mansoor NamaziDepartment of Cardiology, School of Medicine, Qom University of Medical sciences, Qom, Iran.
Shadi ZiaieDepartment of Clinical pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Science, Tehran, Iran.
Raana Jafari-MoghaddamDepartment of Clinical pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Science, Tehran, Iran.
Saeid KalantariAntimicrobial Resistance Research Center, Iran University of Medical Science, Tehran, Iran.
Mohammad MemarianDepartment of Internal Medicine, School of Medicine, Semnan University of Medical sciences, Semnan, Iran.
Javad KhodadadiDepartment of Infectious disease, School of Medicine, Qom University of Medical sciences, Qom, Iran.
Mohammad Hossein AfshariSchool of Medicine, Qom University of Medical sciences, Qom, Iran.
Mansooreh Momen-HeraviInfectious Diseases Research Center, School of Medicine, Kashan University of Medical Science, Kashan, Iran.
Niusha BehzadsereshtSchool of Medicine, Kashan University of Medical Science, Kashan, Iran.
Ahmad Reza MobayenDepartment of Infectious disease, School of Medicine, Zanjan University of Medical sciences, Zanjan, Iran.
Abolfazl MozafariDepartment of Medical sciences, Qom Branch, Islamic Azad University, Qom, Iran.
Fatemeh MovasaghiDepartment of Medical sciences, Qom Branch, Islamic Azad University, Qom, Iran.
Maryam Haddadzadeh ShoushtariDepartment of Infectious disease, School of Medicine, Ahvaz Jundishapur university of medical sciences, Ahvaz, Iran.
Javad MoazenSchool of Medicine, Dezful University of Medical Science, Dezful, Iran.
Baqiyatallah University of Medical Sciences · IRIran University of Medical Sciences · IRQazvin University of Medical Sciences · IRUniversity of Tabriz · IRDezful University of Medical Sciences · IRBiotechnology Research Center · IRKashan University of Medical Sciences · IRRasool Akram Hospital · IRResearch Institute for Endocrine Sciences · IRUniversity of Isfahan · IRUniversity of Tehran · IR
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe examined the safety and efficacy of a treatment protocol containing Favipiravir for the treatment of SARS-CoV-2.
methodsWe did a multicenter randomized open-labeled clinical trial on moderate to severe cases infections of SARS-CoV-2. Patients with typical ground glass appearance on chest computerized tomography scan (CT scan) and oxygen saturation (SpO
results380 patients were randomly allocated into Favipiravir (193) and Lopinavir/Ritonavir (187) groups in 13 centers. The number of deaths, intubations, and ICU admissions were not significantly different (26, 27, 31 and 21, 17, 25 respectively). Mean hospital stay was also not different (7.9 days [SD = 6] in the Favipiravir and 8.1 [SD = 6.5] days in Lopinavir/Ritonavir groups) (p = 0.61). Time to clinical recovery in the Favipiravir group was similar to Lopinavir/Ritonavir group (HR = 0.94, 95% CI 0.75 - 1.17) and likewise the changes in the daily SpO
Indexed as
COVID-19 Drug TreatmentAdolescentAdultAgedAged, 80 and overAmidesAntiviral AgentsDrug Therapy, CombinationFemaleHumansHydroxychloroquineIntubationKaplan-Meier EstimateLength of StayLopinavirMaleAmidesAntiviral AgentsfavipiravirHydroxychloroquineLopinavirOxygenPyrazinesRitonavirClinical trialCovid19FavipiravirHydroxychloroquineLopinavirRitonavirSARS-CoV-2
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.